Xiaoli Chai

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng et al. · The Lancet Oncology · 2020 · 638 citations

Medicine, Oncology, Pharmacology +9

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Feng Wang, Shukui Qin, Xinchen Sun et al. · Journal of Hematology & Oncology · 2020 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17

EGF-mediated EGFR/ERK signaling pathway promotes germinative cell proliferation in Echinococcus multilocularis that contributes to larval growth and development

Zhe Cheng, Fan Liu, Xiu Li et al. · PLoS neglected tropical diseases · 2017 · 54 citations · Full text

Life Sciences, Cell Biology, Microbiology +17

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression

Zhenggang Ren, Shukui Qin, Zhiqiang Meng et al. · Liver Cancer · 2021 · 26 citations · Full text

Medicine, Oncology, Pharmacology +15

A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.

Feng Bi, Meng Qiu, Xiaoli Chai et al. · Journal of Clinical Oncology · 2017 · 10 citations

Pharmacy, Oncology, Pharmacology +14